Plain-English translation of NCT02553642 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial investigated how well — an immunotherapy drug — worked in patients with advanced melanoma or bladder cancer. The researchers studied the genetic makeup of participants' tumors to understand which features could help predict who would respond well to the medication and who might not benefit as much.
Immunotherapy doesn't work equally well for all patients, and doctors need better ways to predict who will benefit before starting treatment. This trial explored whether looking at specific genetic changes in a tumor could help identify patients most likely to respond to this medication.
Participants with melanoma received combination immunotherapy drugs every 3 weeks for 4 doses, then continued on a single medication every 2 weeks or monthly for up to 2 years. Participants with bladder cancer received the single medication every 2 weeks for up to 2 years. Before starting treatment, all participants had a tumor biopsy so researchers could examine the genetic characteristics of their cancer. Throughout the study, participants had regular imaging scans, blood tests, and clinic visits to monitor how well the treatment was working and to watch for side effects.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States